The perception and management of drug safety risks /
| Άλλοι συγγραφείς: | , |
|---|---|
| Μορφή: | Βιβλίο |
| Γλώσσα: | English |
| Έκδοση: |
Berlin, Heidelberg ; New York :
Springer Berlin Heidelberg,
1989.
|
| Σειρά: | Health Systems Research ;
1431-4002 |
| Θέματα: |
MARC
| LEADER | 00000nam a2200000 u 4500 | ||
|---|---|---|---|
| 001 | 4904 | ||
| 003 | GrATPDL | ||
| 005 | 20230926190644.0 | ||
| 008 | 890105s1989 gw a b 101 0 eng | ||
| 020 | |a 3540505342 | ||
| 040 | |a GrATPDL |d ΕΘΝΙΚΗ ΣΧΟΛΗ ΔΗΜΟΣΙΑΣ ΥΓΕΙΑΣ-ΚΕΝΤΡΙΚΗ ΒΙΒΛΙΟΘΗΚΗ |c ΠΑΝΕΠΙΣΤΗΜΙΟΥΠΟΛΗ ΑΘΗΝΩΝ | ||
| 041 | 0 | |a eng | |
| 082 | |a 615.19 | ||
| 245 | 0 | 4 | |a The perception and management of drug safety risks / |c edited by Bruno Horisberger, Rolf Dinkel. |
| 260 | |a Berlin, Heidelberg ; |a New York : |b Springer Berlin Heidelberg, |c 1989. | ||
| 300 | |a xxiii, 210 σ. : |b εικ., διαγρ., πιν. ; |c 25 εκ. | ||
| 490 | 0 | |a Health Systems Research ; |v 1431-4002 | |
| 500 | |a Περιέχει παράρτημα με τα Βιογραφικά των συγγραφέων, γλωσσαριο και πίνακες. | ||
| 504 | |a Βιβλιογραφία : σ.191-201. | ||
| 505 | |a Opening Address -- I: Society and the Benefit/Risk Relationship -- 1. Acceptable Risk in Society -- 2. A Broad Framework for Confronting Health Risks -- 3. Communicating the Risks and Benefits of Technology: The Case of Pharmaceuticals -- 4. Overview of the Drug Safety Issue and Ciba-Geigy’s Response: RAD-AR -- 5. Summary of Part I: Presentations and Discussions -- II: Benefit/Risk Analysis and Appraisal -- 6. Limitations of Available Sources of Data on Prescription Drug Safety -- 7. Strategies, Designs, Criteria, Tactics and Statistics to be Considered when Evaluating Scientific Evidence -- 8. Statistics in Drug Risk Research: The Background of Pharmacoepidemiology -- 9. Industry-Sponsored Risk Institutes -- 10. The Feldene Experience: A Case Study -- 11. Risk Perception of Prescription Drugs: Report on a Survey in Sweden -- 12. Risk Perception of Prescription Drugs: Report on Surveys in Japan -- 13. Scientific and Political Components of Regulatory Decision Making: General Considerations -- 14. Scientific and Political Components of Regulatory Decision Making: The United States Experience -- 15. Summary of Part II: Presentations and Discussions -- III: Current Challenges -- 16. Professional Drug Information: A Consumer Perspective -- 17. Going Patient, Going Public -- 18. Reporting Adverse Drug Reactions: The Media Approach -- 19. What Can Be Learned from Drug Safety Issues? -- 20. Summary of Part III: Presentations and Discussions -- IV: Responding to the Issues -- 21. Editor’s Note -- 22. Pharmacoepidemiology -- 23. Risk Perception Analysis -- 24. Communicating the Benefit/Risk Relationship -- 25. Risk Appraisal on an International Scale -- V: Outlook -- 26. The Wolfsberg Questions -- VI: Annex -- 27. Curriculum Vitae of Authors -- 28. Bibliography -- 29. Subject Index -- 30. A Handbook of International Data Sources for Drug Benefit/Risk Assessment. | ||
| 650 | 0 | |a Health risk assessment. |9 4495 | |
| 650 | 0 | |a Εκτίμηση κινδύνου για την υγεία. |9 4496 | |
| 650 | 0 | |a Φαρμακολογία. |9 3270 | |
| 650 | 0 | |a Pharmacology. |9 3269 | |
| 700 | 1 | |a Horisberger, Bruno. |e Επιμελητής |9 5825 | |
| 700 | 1 | |a Dinkel, Rolf. |e Επιμελητής |9 5826 | |
| 942 | |2 ddc |c BK |h 615.19 PER |6 615_190000000000000_PER | ||
| 952 | |0 0 |1 0 |2 ddc |4 0 |6 615_190000000000000_PER |7 1 |9 5378 |a MAIN |b MAIN |d 2020-01-10 |l 0 |o 615.19 PER |p 00005359 |r 2020-01-10 |t 1 |w 2020-01-10 |y BK | ||
| 999 | |c 5372 |d 5372 | ||
Εγγραφή στο Ευρετήριο Αναζήτησης
| _version_ | 1784614218894409728 |
|---|---|
| author2 | Horisberger, Bruno Dinkel, Rolf |
| author2_role | Επιμελητής Επιμελητής |
| author2_variant | b h bh r d rd |
| author_facet | Horisberger, Bruno Dinkel, Rolf |
| author_sort | Horisberger, Bruno |
| building | Campus Library III |
| collection | LIB3 Catalog |
| contents | Opening Address -- I: Society and the Benefit/Risk Relationship -- 1. Acceptable Risk in Society -- 2. A Broad Framework for Confronting Health Risks -- 3. Communicating the Risks and Benefits of Technology: The Case of Pharmaceuticals -- 4. Overview of the Drug Safety Issue and Ciba-Geigy’s Response: RAD-AR -- 5. Summary of Part I: Presentations and Discussions -- II: Benefit/Risk Analysis and Appraisal -- 6. Limitations of Available Sources of Data on Prescription Drug Safety -- 7. Strategies, Designs, Criteria, Tactics and Statistics to be Considered when Evaluating Scientific Evidence -- 8. Statistics in Drug Risk Research: The Background of Pharmacoepidemiology -- 9. Industry-Sponsored Risk Institutes -- 10. The Feldene Experience: A Case Study -- 11. Risk Perception of Prescription Drugs: Report on a Survey in Sweden -- 12. Risk Perception of Prescription Drugs: Report on Surveys in Japan -- 13. Scientific and Political Components of Regulatory Decision Making: General Considerations -- 14. Scientific and Political Components of Regulatory Decision Making: The United States Experience -- 15. Summary of Part II: Presentations and Discussions -- III: Current Challenges -- 16. Professional Drug Information: A Consumer Perspective -- 17. Going Patient, Going Public -- 18. Reporting Adverse Drug Reactions: The Media Approach -- 19. What Can Be Learned from Drug Safety Issues? -- 20. Summary of Part III: Presentations and Discussions -- IV: Responding to the Issues -- 21. Editor’s Note -- 22. Pharmacoepidemiology -- 23. Risk Perception Analysis -- 24. Communicating the Benefit/Risk Relationship -- 25. Risk Appraisal on an International Scale -- V: Outlook -- 26. The Wolfsberg Questions -- VI: Annex -- 27. Curriculum Vitae of Authors -- 28. Bibliography -- 29. Subject Index -- 30. A Handbook of International Data Sources for Drug Benefit/Risk Assessment. |
| dewey-full | 615.19 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.19 |
| dewey-search | 615.19 |
| dewey-sort | 3615.19 |
| dewey-tens | 610 - Medicine and health |
| format | Book |
| fullrecord | {"leader":"03387nam a2200313 u 4500","fields":[{"001":"4904"},{"003":"GrATPDL"},{"005":"20230926190644.0"},{"008":"890105s1989 gw a b 101 0 eng "},{"020":{"subfields":[{"a":"3540505342"}],"ind1":" ","ind2":" "}},{"040":{"subfields":[{"a":"GrATPDL"},{"d":"\u0395\u0398\u039d\u0399\u039a\u0397 \u03a3\u03a7\u039f\u039b\u0397 \u0394\u0397\u039c\u039f\u03a3\u0399\u0391\u03a3 \u03a5\u0393\u0395\u0399\u0391\u03a3-\u039a\u0395\u039d\u03a4\u03a1\u0399\u039a\u0397 \u0392\u0399\u0392\u039b\u0399\u039f\u0398\u0397\u039a\u0397"},{"c":"\u03a0\u0391\u039d\u0395\u03a0\u0399\u03a3\u03a4\u0397\u039c\u0399\u039f\u03a5\u03a0\u039f\u039b\u0397 \u0391\u0398\u0397\u039d\u03a9\u039d"}],"ind1":" ","ind2":" "}},{"041":{"subfields":[{"a":"eng"}],"ind1":"0","ind2":" "}},{"082":{"subfields":[{"a":"615.19"}],"ind1":" ","ind2":" "}},{"245":{"subfields":[{"a":"The perception and management of drug safety risks /"},{"c":"edited by Bruno Horisberger, Rolf Dinkel."}],"ind1":"0","ind2":"4"}},{"260":{"subfields":[{"a":"Berlin, Heidelberg ;"},{"a":"New York :"},{"b":"Springer Berlin Heidelberg,"},{"c":"1989."}],"ind1":" ","ind2":" "}},{"300":{"subfields":[{"a":"xxiii, 210 \u03c3. :"},{"b":"\u03b5\u03b9\u03ba., \u03b4\u03b9\u03b1\u03b3\u03c1., \u03c0\u03b9\u03bd. ;"},{"c":"25 \u03b5\u03ba."}],"ind1":" ","ind2":" "}},{"490":{"subfields":[{"a":"Health Systems Research ;"},{"v":"1431-4002"}],"ind1":"0","ind2":" "}},{"500":{"subfields":[{"a":"\u03a0\u03b5\u03c1\u03b9\u03ad\u03c7\u03b5\u03b9 \u03c0\u03b1\u03c1\u03ac\u03c1\u03c4\u03b7\u03bc\u03b1 \u03bc\u03b5 \u03c4\u03b1 \u0392\u03b9\u03bf\u03b3\u03c1\u03b1\u03c6\u03b9\u03ba\u03ac \u03c4\u03c9\u03bd \u03c3\u03c5\u03b3\u03b3\u03c1\u03b1\u03c6\u03ad\u03c9\u03bd, \u03b3\u03bb\u03c9\u03c3\u03c3\u03b1\u03c1\u03b9\u03bf \u03ba\u03b1\u03b9 \u03c0\u03af\u03bd\u03b1\u03ba\u03b5\u03c2."}],"ind1":" ","ind2":" "}},{"504":{"subfields":[{"a":"\u0392\u03b9\u03b2\u03bb\u03b9\u03bf\u03b3\u03c1\u03b1\u03c6\u03af\u03b1 : \u03c3.191-201."}],"ind1":" ","ind2":" "}},{"505":{"subfields":[{"a":"Opening Address -- I: Society and the Benefit/Risk Relationship -- 1. Acceptable Risk in Society -- 2. A Broad Framework for Confronting Health Risks -- 3. Communicating the Risks and Benefits of Technology: The Case of Pharmaceuticals -- 4. Overview of the Drug Safety Issue and Ciba-Geigy\u2019s Response: RAD-AR -- 5. Summary of Part I: Presentations and Discussions -- II: Benefit/Risk Analysis and Appraisal -- 6. Limitations of Available Sources of Data on Prescription Drug Safety -- 7. Strategies, Designs, Criteria, Tactics and Statistics to be Considered when Evaluating Scientific Evidence -- 8. Statistics in Drug Risk Research: The Background of Pharmacoepidemiology -- 9. Industry-Sponsored Risk Institutes -- 10. The Feldene Experience: A Case Study -- 11. Risk Perception of Prescription Drugs: Report on a Survey in Sweden -- 12. Risk Perception of Prescription Drugs: Report on Surveys in Japan -- 13. Scientific and Political Components of Regulatory Decision Making: General Considerations -- 14. Scientific and Political Components of Regulatory Decision Making: The United States Experience -- 15. Summary of Part II: Presentations and Discussions -- III: Current Challenges -- 16. Professional Drug Information: A Consumer Perspective -- 17. Going Patient, Going Public -- 18. Reporting Adverse Drug Reactions: The Media Approach -- 19. What Can Be Learned from Drug Safety Issues? -- 20. Summary of Part III: Presentations and Discussions -- IV: Responding to the Issues -- 21. Editor\u2019s Note -- 22. Pharmacoepidemiology -- 23. Risk Perception Analysis -- 24. Communicating the Benefit/Risk Relationship -- 25. Risk Appraisal on an International Scale -- V: Outlook -- 26. The Wolfsberg Questions -- VI: Annex -- 27. Curriculum Vitae of Authors -- 28. Bibliography -- 29. Subject Index -- 30. A Handbook of International Data Sources for Drug Benefit/Risk Assessment."}],"ind1":" ","ind2":" "}},{"650":{"subfields":[{"a":"Health risk assessment."},{"9":"4495"}],"ind1":" ","ind2":"0"}},{"650":{"subfields":[{"a":"\u0395\u03ba\u03c4\u03af\u03bc\u03b7\u03c3\u03b7 \u03ba\u03b9\u03bd\u03b4\u03cd\u03bd\u03bf\u03c5 \u03b3\u03b9\u03b1 \u03c4\u03b7\u03bd \u03c5\u03b3\u03b5\u03af\u03b1."},{"9":"4496"}],"ind1":" ","ind2":"0"}},{"650":{"subfields":[{"a":"\u03a6\u03b1\u03c1\u03bc\u03b1\u03ba\u03bf\u03bb\u03bf\u03b3\u03af\u03b1."},{"9":"3270"}],"ind1":" ","ind2":"0"}},{"650":{"subfields":[{"a":"Pharmacology."},{"9":"3269"}],"ind1":" ","ind2":"0"}},{"700":{"subfields":[{"a":"Horisberger, Bruno."},{"e":"\u0395\u03c0\u03b9\u03bc\u03b5\u03bb\u03b7\u03c4\u03ae\u03c2"},{"9":"5825"}],"ind1":"1","ind2":" "}},{"700":{"subfields":[{"a":"Dinkel, Rolf."},{"e":"\u0395\u03c0\u03b9\u03bc\u03b5\u03bb\u03b7\u03c4\u03ae\u03c2"},{"9":"5826"}],"ind1":"1","ind2":" "}},{"942":{"subfields":[{"2":"ddc"},{"c":"BK"},{"h":"615.19 PER"},{"6":"615_190000000000000_PER"}],"ind1":" ","ind2":" "}},{"952":{"subfields":[{"0":"0"},{"1":"0"},{"2":"ddc"},{"4":"0"},{"6":"615_190000000000000_PER"},{"7":"1"},{"9":"5378"},{"a":"MAIN"},{"b":"MAIN"},{"d":"2020-01-10"},{"l":"0"},{"o":"615.19 PER"},{"p":"00005359"},{"r":"2020-01-10"},{"t":"1"},{"w":"2020-01-10"},{"y":"BK"}],"ind1":" ","ind2":" "}},{"999":{"subfields":[{"c":"5372"},{"d":"5372"}],"ind1":" ","ind2":" "}}]}
|
| id | lib3_5372 |
| illustrated | Illustrated |
| institution | University of West Attica |
| isbn | 3540505342 |
| language | English |
| physical | xxiii, 210 σ. : εικ., διαγρ., πιν. ; 25 εκ. |
| publishDate | 1989 |
| publisher | Springer Berlin Heidelberg, |
| record_format | marc |
| series2 | Health Systems Research ; |
| spelling | The perception and management of drug safety risks / edited by Bruno Horisberger, Rolf Dinkel. Berlin, Heidelberg ; New York : Springer Berlin Heidelberg, 1989. xxiii, 210 σ. : εικ., διαγρ., πιν. ; 25 εκ. Health Systems Research ; 1431-4002 Περιέχει παράρτημα με τα Βιογραφικά των συγγραφέων, γλωσσαριο και πίνακες. Βιβλιογραφία : σ.191-201. Opening Address -- I: Society and the Benefit/Risk Relationship -- 1. Acceptable Risk in Society -- 2. A Broad Framework for Confronting Health Risks -- 3. Communicating the Risks and Benefits of Technology: The Case of Pharmaceuticals -- 4. Overview of the Drug Safety Issue and Ciba-Geigy’s Response: RAD-AR -- 5. Summary of Part I: Presentations and Discussions -- II: Benefit/Risk Analysis and Appraisal -- 6. Limitations of Available Sources of Data on Prescription Drug Safety -- 7. Strategies, Designs, Criteria, Tactics and Statistics to be Considered when Evaluating Scientific Evidence -- 8. Statistics in Drug Risk Research: The Background of Pharmacoepidemiology -- 9. Industry-Sponsored Risk Institutes -- 10. The Feldene Experience: A Case Study -- 11. Risk Perception of Prescription Drugs: Report on a Survey in Sweden -- 12. Risk Perception of Prescription Drugs: Report on Surveys in Japan -- 13. Scientific and Political Components of Regulatory Decision Making: General Considerations -- 14. Scientific and Political Components of Regulatory Decision Making: The United States Experience -- 15. Summary of Part II: Presentations and Discussions -- III: Current Challenges -- 16. Professional Drug Information: A Consumer Perspective -- 17. Going Patient, Going Public -- 18. Reporting Adverse Drug Reactions: The Media Approach -- 19. What Can Be Learned from Drug Safety Issues? -- 20. Summary of Part III: Presentations and Discussions -- IV: Responding to the Issues -- 21. Editor’s Note -- 22. Pharmacoepidemiology -- 23. Risk Perception Analysis -- 24. Communicating the Benefit/Risk Relationship -- 25. Risk Appraisal on an International Scale -- V: Outlook -- 26. The Wolfsberg Questions -- VI: Annex -- 27. Curriculum Vitae of Authors -- 28. Bibliography -- 29. Subject Index -- 30. A Handbook of International Data Sources for Drug Benefit/Risk Assessment. Health risk assessment. 4495 Εκτίμηση κινδύνου για την υγεία. 4496 Φαρμακολογία. 3270 Pharmacology. 3269 Horisberger, Bruno. Επιμελητής 5825 Dinkel, Rolf. Επιμελητής 5826 |
| spellingShingle | The perception and management of drug safety risks / Opening Address -- I: Society and the Benefit/Risk Relationship -- 1. Acceptable Risk in Society -- 2. A Broad Framework for Confronting Health Risks -- 3. Communicating the Risks and Benefits of Technology: The Case of Pharmaceuticals -- 4. Overview of the Drug Safety Issue and Ciba-Geigy’s Response: RAD-AR -- 5. Summary of Part I: Presentations and Discussions -- II: Benefit/Risk Analysis and Appraisal -- 6. Limitations of Available Sources of Data on Prescription Drug Safety -- 7. Strategies, Designs, Criteria, Tactics and Statistics to be Considered when Evaluating Scientific Evidence -- 8. Statistics in Drug Risk Research: The Background of Pharmacoepidemiology -- 9. Industry-Sponsored Risk Institutes -- 10. The Feldene Experience: A Case Study -- 11. Risk Perception of Prescription Drugs: Report on a Survey in Sweden -- 12. Risk Perception of Prescription Drugs: Report on Surveys in Japan -- 13. Scientific and Political Components of Regulatory Decision Making: General Considerations -- 14. Scientific and Political Components of Regulatory Decision Making: The United States Experience -- 15. Summary of Part II: Presentations and Discussions -- III: Current Challenges -- 16. Professional Drug Information: A Consumer Perspective -- 17. Going Patient, Going Public -- 18. Reporting Adverse Drug Reactions: The Media Approach -- 19. What Can Be Learned from Drug Safety Issues? -- 20. Summary of Part III: Presentations and Discussions -- IV: Responding to the Issues -- 21. Editor’s Note -- 22. Pharmacoepidemiology -- 23. Risk Perception Analysis -- 24. Communicating the Benefit/Risk Relationship -- 25. Risk Appraisal on an International Scale -- V: Outlook -- 26. The Wolfsberg Questions -- VI: Annex -- 27. Curriculum Vitae of Authors -- 28. Bibliography -- 29. Subject Index -- 30. A Handbook of International Data Sources for Drug Benefit/Risk Assessment. Health risk assessment. 4495 Εκτίμηση κινδύνου για την υγεία. 4496 Φαρμακολογία. 3270 Pharmacology. 3269 |
| title | The perception and management of drug safety risks / |
| title_auth | The perception and management of drug safety risks / |
| title_full | The perception and management of drug safety risks / edited by Bruno Horisberger, Rolf Dinkel. |
| title_fullStr | The perception and management of drug safety risks / edited by Bruno Horisberger, Rolf Dinkel. |
| title_full_unstemmed | The perception and management of drug safety risks / edited by Bruno Horisberger, Rolf Dinkel. |
| title_short | The perception and management of drug safety risks / |
| title_sort | perception and management of drug safety risks |
| topic | Health risk assessment. 4495 Εκτίμηση κινδύνου για την υγεία. 4496 Φαρμακολογία. 3270 Pharmacology. 3269 |
| topic_facet | Health risk assessment. Εκτίμηση κινδύνου για την υγεία. Φαρμακολογία. Pharmacology. |
| work_keys_str_mv | AT horisbergerbruno theperceptionandmanagementofdrugsafetyrisks AT dinkelrolf theperceptionandmanagementofdrugsafetyrisks AT horisbergerbruno perceptionandmanagementofdrugsafetyrisks AT dinkelrolf perceptionandmanagementofdrugsafetyrisks |